- Home
- CGEM vs EU Comparison
CGEM vs EU Comparison
Compare CGEM & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- EU
- Stock Information
- Founded
- CGEM 2016
- EU 2009
- Country
- CGEM United States
- EU United States
- Employees
- CGEM N/A
- EU N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- EU Other Metals and Minerals
- Sector
- CGEM Health Care
- EU Basic Materials
- Exchange
- CGEM Nasdaq
- EU Nasdaq
- Market Cap
- CGEM 530.0M
- EU 538.3M
- IPO Year
- CGEM 2021
- EU N/A
- Fundamental
- Price
- CGEM $8.18
- EU $3.04
- Analyst Decision
- CGEM Strong Buy
- EU Strong Buy
- Analyst Count
- CGEM 6
- EU 1
- Target Price
- CGEM $28.17
- EU $2.75
- AVG Volume (30 Days)
- CGEM 331.3K
- EU 2.8M
- Earning Date
- CGEM 08-07-2025
- EU 08-13-2025
- Dividend Yield
- CGEM N/A
- EU N/A
- EPS Growth
- CGEM N/A
- EU N/A
- EPS
- CGEM N/A
- EU N/A
- Revenue
- CGEM N/A
- EU $46,179,000.00
- Revenue This Year
- CGEM N/A
- EU $27.46
- Revenue Next Year
- CGEM N/A
- EU $140.12
- P/E Ratio
- CGEM N/A
- EU N/A
- Revenue Growth
- CGEM N/A
- EU N/A
- 52 Week Low
- CGEM $6.85
- EU $1.01
- 52 Week High
- CGEM $20.96
- EU $4.44
- Technical
- Relative Strength Index (RSI)
- CGEM 54.88
- EU 64.06
- Support Level
- CGEM $7.42
- EU $2.91
- Resistance Level
- CGEM $8.70
- EU $3.20
- Average True Range (ATR)
- CGEM 0.38
- EU 0.17
- MACD
- CGEM 0.09
- EU 0.00
- Stochastic Oscillator
- CGEM 63.12
- EU 76.47
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.